SEC Comment Letter for Quoin Pharmaceuticals, Ltd. (QNRX) (CIK 0001671502) (QNRX) — Aug 10, 2017
Quoin Pharmaceuticals, Ltd. (QNRX) (CIK 0001671502)
Date: Aug. 10, 2017 · CIK: 0001671502 · Accession: 0000000000-17-028232
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-219614
Letter
Mail Stop 3030 August 9, 2017 Via E -mail Dr. Shai Yarkoni Chief Executive Officer Cellect Biotechnology Ltd. 23 Hata’as Street Kfar Saba, Israel 44425
Re: Cellect Biotechnology Ltd. Registration Statement on Form F-3 Filed August 1, 2017 File No. 333-219614
Dear Dr. Yarkoni :
This is to advise you that we have not reviewed and will not review your registration statement .
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Caleb French at (202) 551 -6947 with any questions.
Sincerely,
/s/ Caleb French for
Show Raw Text
Mail Stop 3030 August 9, 2017 Via E -mail Dr. Shai Yarkoni Chief Executive Officer Cellect Biotechnology Ltd. 23 Hata’as Street Kfar Saba, Israel 44425 Re: Cellect Biotechnology Ltd. Registration Statement on Form F-3 Filed August 1, 2017 File No. 333-219614 Dear Dr. Yarkoni : This is to advise you that we have not reviewed and will not review your registration statement . Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Caleb French at (202) 551 -6947 with any questions. Sincerely, /s/ Caleb French for Amanda Ravitz Assistant Director Office of Electronics and Machinery cc: Gary Emmanuel, Esq. McDermott Will & Emery LLP